| abstract |
By administering the dipeptidyl peptidase-4 inhibitor pharmaceutical composition to subjects who are certified for over-the-counter availability of the dipeptidyl peptidase-4 inhibitor pharmaceutical composition, the blood glucose of subjects who need to be lowered is lowered. A method for is provided. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition comprises saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition comprises (1S, 3S, 5S) -2-[(2S) -2-amino-2- (3-hydroxy-1-adamantyl) acetyl. ] -2-Azabicyclo [3.1.0] Contains hexane-3-carbonitrile, or a pharmaceutically acceptable salt thereof. |